Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Jiri Minarik"'
Autor:
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Spicka
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to M
Externí odkaz:
https://doaj.org/article/ac4fa0e66df54bf9a47e4350692f9954
Autor:
Paul G. Richardson, Aurore Perrot, Jesus San Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Chenda Morisse, Kenneth C. Anderson
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The primary and pre-specified updated analyses of ICARIA-MM (NCT02990338) demonstrated improved progression-free survival and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomali
Externí odkaz:
https://doaj.org/article/2cdeb822507640969679ff3be53cc866
Autor:
Petra Luzna, Denisa Weiser Drozdkova, Pavla Flodrova, Katarina Ondruskova, Ivo Uberall, Jiri Minarik, Zdenek Kolar, Katerina Smesny Trtkova
Publikováno v:
Biomedical Papers, Vol 167, Iss 1, Pp 43-49 (2023)
Aims. The aim of this study was to compare the expression profile of selected DNA methyltransferases and global DNA methylation status in patients with different phases of multiple myeloma (MM) . For the analysis, different cellular populations inclu
Externí odkaz:
https://doaj.org/article/da9369f7aa9d4fa88aba3942419199aa
Autor:
Ivan Spicka, Ido Lapidot, Maximilian Merz, Jakub Radocha, Martin Stork, Tomas Jelínek, Alexandra Jungova, Jiri Minarik, Jan Soukup, Michel Van Speybroeck, Nolen Perualila, Joris Diels, João Duarte Mendes, Kirsten van Nimwegen, Kai Strobel, Sebastien Wischlen, Henrik Sliwka, Blanca Gros Otero, Roman Hajek
Publikováno v:
HemaSphere, Vol 7, p e258126d (2023)
Externí odkaz:
https://doaj.org/article/182f7353616142faae8ea93f217fa58a
Autor:
Tereza Popková, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Petr Pavlíček, Tomas Jelínek, Marta Krejčí, Jan Straub, Vladimir Maisnar, Tereza Dekojová, Tomáš Pika, Jan Soukup, Lenka Pospíšilová, Roman Hájek
Publikováno v:
HemaSphere, Vol 7, p e0151603 (2023)
Externí odkaz:
https://doaj.org/article/bccb80a8722b403495d8299166e323a6
Autor:
Eva Kriegova, Regina Fillerova, Jiri Minarik, Jakub Savara, Jirina Manakova, Anna Petrackova, Martin Dihel, Jana Balcarkova, Petra Krhovska, Tomas Pika, Petr Gajdos, Marek Behalek, Michal Vasinek, Tomas Papajik
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype of multiple myeloma (MM). EMM is frequently associated with high-risk cytogenetics, but their complex genomic architecture is largely unexplored. We us
Externí odkaz:
https://doaj.org/article/37daeaba58954dc38da078cfcf51a94f
Autor:
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar, Roman Hajek
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RR
Externí odkaz:
https://doaj.org/article/f4b149c2be57476793d1f90b53292d39
Autor:
Jiri Minarik, Ludek Pour, Vladimir Maisnar, Ivan Spicka, Alexandra Jungova, Tomas Jelinek, Lucie Brozova, Petra Krhovska, Vlastimil Scudla, Roman Hajek
Publikováno v:
Biomedical Papers, Vol 163, Iss 3, Pp 279-283 (2019)
Objective: The treatment of relapsed and refractory multiple myeloma (RRMM) remains challenging. The outcomes in highly pretreated populations are unsatisfactory and there is urgent need for novel and safe therapeutic approaches. Recently, daratumuma
Externí odkaz:
https://doaj.org/article/ba00345e23af4c23b574b7f1d59203c2
Autor:
Martin Stork, Sabina Sevcikova, Tomas Jelinek, Jiri Minarik, Jakub Radocha, Tomas Pika, Lenka Pospisilova, Ivan Spicka, Jan Straub, Petr Pavlicek, Alexandra Jungova, Zdenka Knechtova, Viera Sandecka, Vladimir Maisnar, Roman Hajek, Ludek Pour
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2535 (2022)
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD
Externí odkaz:
https://doaj.org/article/e364609dd50643da92cbb311d623a43f
Autor:
Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Pospisilova, Petra Krhovska, Denisa Novakova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Vladimir Maisnar, Roman Hajek
Publikováno v:
Cancers, Vol 14, Iss 20, p 5165 (2022)
Background: We confirmed the benefit of addition of ixazomib to lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM) in unselected real-world population. We report the final analysis for overall survival (OS
Externí odkaz:
https://doaj.org/article/61e15198e39d4b7ea3ceb812c161aa48